Drug Guidance
Blinatumomab for newly diagnosed B-precursor acute lymphoblastic leukaemia in the consolidation phase of chemotherapy
Condition
Blood and Immune System
Cancer
6 February 2026
-
Published on 06 Feb 2026
Last Updated on 06 Feb 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Blinatumomab 35 mcg powder for infusion for treating newly diagnosed patients with CD-19-positive B-precursor acute lymphoblastic leukaemia in the front-line consolidation phase of multiphase chemotherapy with documented complete remission (CR) or CR with incomplete haematologic recovery (CRi) after induction therapy for a maximum of four cycles in total.
in view of acceptable clinical effectiveness and safety, and an acceptable pricing proposal by the company.
Funding status
Blinatumomab 35 mcg powder for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
Clinical indication, subsidy class and MediShield Life claim limit for blinatumomab are provided in the Annex.